{"id":"tp-42866","type":"article-newspaper","title":"Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/42866","datePublished":"2026-10-28T19:23:49.000Z","dateModified":"2026-10-28T19:23:49.000Z","language":"en","abstract":"The Phase 3 data involved certain patients with head and neck cancer. Petosemtamab is a bispecific antibody therapy.","section":"Business","references":[]}